Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag Extension in Severe Aplastic Anemia
NCT04961710Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Sep 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of hetrombopag in aplastic anemia (2 arms), sponsored by Hengrui. Primary endpoints: Ratio of subjects with clonal evolution at 18 months, Serious Infection Events at 3 years and 2 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT04961710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961710.